Cargando…
小细胞肺癌分子分型研究进展
Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with th...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560980/ https://www.ncbi.nlm.nih.gov/pubmed/34696546 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36 |
_version_ | 1784593036495290368 |
---|---|
collection | PubMed |
description | Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with the gradual deepening understanding on the molecular mechanism of SCLC and multi-omics data, it is proposed that molecular typing can be carried out according to the differential expression of key transcription factors, including SCLC-A, SCLC-N, SCLC-P and SCLC-I subtypes. Molecular typing of SCLC and its clinical application will help doctors to further optimize the detailed diagnosis and treatment plan of SCLC patients, so as to prolong the survival time and improve the quality of life of patients. |
format | Online Article Text |
id | pubmed-8560980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85609802021-11-10 小细胞肺癌分子分型研究进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is a highly aggressive and fatal malignant tumor. It has the characteristics of complex etiology, low differentiation, high malignancy, fast growth, strong invasiveness, early metastasis and acquired drug resistance, resulting in poor prognosis. In recent years, with the gradual deepening understanding on the molecular mechanism of SCLC and multi-omics data, it is proposed that molecular typing can be carried out according to the differential expression of key transcription factors, including SCLC-A, SCLC-N, SCLC-P and SCLC-I subtypes. Molecular typing of SCLC and its clinical application will help doctors to further optimize the detailed diagnosis and treatment plan of SCLC patients, so as to prolong the survival time and improve the quality of life of patients. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560980/ /pubmed/34696546 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 小细胞肺癌分子分型研究进展 |
title | 小细胞肺癌分子分型研究进展 |
title_full | 小细胞肺癌分子分型研究进展 |
title_fullStr | 小细胞肺癌分子分型研究进展 |
title_full_unstemmed | 小细胞肺癌分子分型研究进展 |
title_short | 小细胞肺癌分子分型研究进展 |
title_sort | 小细胞肺癌分子分型研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560980/ https://www.ncbi.nlm.nih.gov/pubmed/34696546 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.36 |
work_keys_str_mv | AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn AT xiǎoxìbāofèiáifēnzifēnxíngyánjiūjìnzhǎn |